文献速递内脏/肾动脉与血管畸形

干预时机、病因及血运重建策略对急性肠系膜缺血结局的影响

The impact of intervention timing, etiology, and revascularization strategy on acute mesenteric ischemia outcomes.
PubMed 文献 · J Vasc Surg · 2025-11-14

本研究在四级医疗中心回顾92例急性肠系膜缺血(AMI)血运重建患者,发现症状发作至血运重建超过48小时者围术期死亡率(39% vs 14%)和短肠综合征发生率(39% vs 12%)显著更高。超过48小时血运重建还与新发AMI、再干预及远期死亡风险升高独立相关。急性血栓性AMI较栓塞性AMI复发和再干预风险更高,但远期死亡率无差异;开放与腔内/逆行开放支架血运重建的远期结局无差异。

要点

  • 症状发作48小时内完成血运重建可降低死亡率、复发、再干预及短肠综合征风险。
  • 急性血栓性AMI较栓塞性AMI复发和再干预风险更高,但远期死亡率无差异。
  • 开放与腔内/逆行开放支架血运重建的远期死亡、复发和再干预无差异。

核心结论

  • 及时诊断并在症状发作48小时内完成血运重建可改善AMI的围术期及远期结局。
  • AMI病因和血运重建策略不影响短期结局,但急性血栓性病因增加复发和再干预风险。

研究设计与样本

  • 回顾性队列研究,纳入2014年1月至2024年12月在四级医疗中心因AMI接受血运重建的92例患者。
  • 排除机械性肠梗阻、创伤、主动脉夹层、肠系膜静脉血栓及非闭塞性肠系膜缺血所致AMI。
  • 按症状发作至血运重建时间、AMI病因和血运重建策略分组比较,采用Kaplan-Meier和Cox回归分析远期结局。

主要发现

  • 症状发作至血运重建超过48小时者围术期死亡率39% vs 14%(P = .012),短肠综合征发生率39% vs 12%(P = .002)。
  • 超过48小时血运重建与远期死亡(HR 2.95;95%CI 1.43-6.07;P = .003)、AMI复发(HR 6.36;95%CI 1.59-25.38;P = .009)和再干预(HR 3.89;95%CI 1.22-12.36;P = .021)风险升高相关。
  • 急性血栓性AMI较栓塞性AMI复发风险(HR 5.97;95%CI 1.05-25.38;P = .048)和再干预风险(HR 8.02;95%CI 1.04-61.95;P = .046)更高,远期死亡无差异(HR 0.79;95%CI 0.34-1.82;P = .577)。
  • 开放与腔内/逆行开放支架血运重建在远期死亡(P = .344)、AMI复发(P = .268)和再干预(P = .685)方面无差异。
  • 围术期死亡的显著预测因素包括年龄(P = .049)、症状发作至血运重建超过48小时(P = .021)和就诊时乳酸水平(P = .029)。

关键数值与推荐

  • 症状发作至血运重建48小时为 inflection point(敏感度81%,特异度63%)。
  • AMI定义为急性症状发作持续时间≤2周的肠系膜缺血。

临床怎么用

  • 对疑似AMI患者应尽快诊断并在48小时内完成血运重建以改善结局。
  • 急性血栓性AMI患者需加强术后监测,警惕复发和再干预风险。
  • 血运重建策略选择可根据技术可行性决定,开放与腔内/逆行开放支架的远期结局无显著差异。

局限性

  • 单中心回顾性研究,样本量较小(92例),可能存在选择偏倚。
  • 48小时截断值基于本中心数据推导,外部推广需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Acute mesenteric ischemia (AMI) is a highly lethal presentation associated with significant perioperative morbidity. Unlike other acute cardiovascular emergencies, outcomes of AMI have shown minimal improvement over time. Among the strategies explored to decrease AMI-related mortality, early diagnosis and prompt surgical revascularization remain most critical for improving both short- and long-term AMI outcomes. This study aims to investigate the impact of time from acute symptom onset to operative intervention on AMI outcomes. METHODS: All patients who underwent revascularization for AMI between January 2014 and December 2024 at our quaternary medical center were identified. AMI was defined as mesenteric ischemia with acute symptom onset of ≤2 weeks duration. Patients with AMI secondary to mechanical bowel obstruction, trauma, aortic dissection, mesenteric venous thrombosis, or nonocclusive mesenteric ischemia were excluded. Patients were then categorized and compared based on the time interval from acute symptom onset to revascularization, etiology of AMI, and revascularization strategy. Kaplan-Meier and Cox regression analyses were used to estimate long-term event rates and evaluate the independent association between exposure variables and long-term outcomes or survival, AMI recurrence, and reintervention. RESULTS: There were 92 patients who met the inclusion criteria. An inflection point at 48 hours was identified (sensitivity 81%, specificity 63%), where patients treated >48 hours after symptom onset had significantly higher rates of perioperative mortality (39% vs 14%; P = .012) and short bowel syndrome (39% vs 12%; P = .002) compared with patients treated within 48 hours of symptom onset. Revascularization >48 hours after acute symptom onset was also associated with higher long-term mortality (hazard ratio [HR], 2.95; 95% confidence interval [CI], 1.43-6.07; P = .003), AMI recurrence (HR, 6.36; 95% CI, 1.59-25.38; P = .009), and reintervention (HR, 3.89; 95% CI, 1.22-12.36; P = .021) compared with revascularization within 48 hours. AMI secondary to acute thrombosis was associated with an increased risk of AMI recurrence (HR, 5.97; 95% CI, 1.05-25.38; P = .048) and reintervention (HR, 8.02; 95% CI, 1.04-61.95; P = .046) compared with embolic AMI, with no difference observed in long-term mortality (HR, 0.79; 95% CI, 0.34-1.82; P = .577). No difference was observed between open and endovascular/retrograde open mesenteric stenting revascularization in long-term mortality (P = .344), AMI recurrence (P = .268), and reintervention (P = .685). Significant predictors of perioperative mortality were age (P = .049), time from acute symptom onset to revascularization >48 hours (P = .021), and lactate level at presentation (P = .029). CONCLUSIONS: Optimal outcomes after AMI can be achieved with timely diagnosis and revascularization. In our experience, diagnosis and intervention within 48 hours decreased mortality, recurrence, reintervention, bowel resection, and short bowel syndrome, and enhanced overall patient outcomes. AMI etiology and management strategy did not affect short-term outcomes, although acute thrombosis was associated with an increased risk of AMI recurrence and reintervention compared with embolic AMI, with no difference in long-term mortality.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chamseddine H, Halabi M, Hamdan H, et al. The impact of intervention timing, etiology, and revascularization strategy on acute mesenteric ischemia outcomes. J Vasc Surg. 2025. PMID: 41242625. doi:10.1016/j.jvs.2025.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。